Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG 2) to arsenic trioxide-induced cell death

Changhai Tian, Ping Gao, Yanhua Zheng, Wen Yue, Xiaohui Wang, Haijing Jin, Quan Chen

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Intracellular redox homeostasis plays a critical role in determining tumor cells' sensitivity to drug-induced apoptosis. Here we investigated the role of thioredoxin-1 (TRX1), a key component of redox regulation, in arsenic trioxide (As 2 O 3)-induced apoptosis. Over-expression of wild-type TRX1 in HepG 2 cells led to the inhibition of As 2 O 3 -induced cytochrome c (cyto c) release, caspase activation and apoptosis, and down-regulation of TRX1 expression by RNAi sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. Interestingly, mutation of the active site of TRX1 from Cys 32/35 to Ser 32/35 converted this molecule from an apoptotic protector to an apoptotic promoter. In an effort to understand the mechanisms of this conversion, we used isolated mitochondria from mouse liver and found that recombinant wild-type TRX1 could protect mitochondria from the apoptotic changes. In contrast, the mutant form of TRX1 alone elicited mitochondria-related apoptotic changes, including the mitochondrial permeability transition pore (mPTP) opening, loss of mitochondrial membrane potential, and cyto c release from mitochondria. These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP. Alteration of TRX1 from its reduced form to oxidized form in vivo by 2,4- dinitrochlorobenzene (DNCB), a specific inhibitor of TRX reductase, also sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. These data suggest that TRX1 plays a central role in regulating apoptosis by blocking cyto c release, and inactivation of TRX1 by either mutation or oxidization of the active site cysteines may sensitize tumor cells to As 2 O 3 -induced apoptosis.

Original languageEnglish (US)
Pages (from-to)458-471
Number of pages14
JournalCell Research
Volume18
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

Thioredoxins
Oxidation-Reduction
Hepatocellular Carcinoma
Cell Death
Apoptosis
Mitochondria
Cytochromes c
Catalytic Domain
arsenic trioxide
Dinitrochlorobenzene
Mutation
Liver Mitochondrion
Mitochondrial Membrane Potential
Caspases
RNA Interference
Cyclosporine
Cysteine
Neoplasms
Oxidoreductases
Homeostasis

Keywords

  • Apoptosis
  • Arsenic trioxide
  • Cytochrome c
  • Hioredoxin-1
  • Mitochondria

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG 2) to arsenic trioxide-induced cell death. / Tian, Changhai; Gao, Ping; Zheng, Yanhua; Yue, Wen; Wang, Xiaohui; Jin, Haijing; Chen, Quan.

In: Cell Research, Vol. 18, No. 4, 01.04.2008, p. 458-471.

Research output: Contribution to journalArticle

Tian, Changhai ; Gao, Ping ; Zheng, Yanhua ; Yue, Wen ; Wang, Xiaohui ; Jin, Haijing ; Chen, Quan. / Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG 2) to arsenic trioxide-induced cell death. In: Cell Research. 2008 ; Vol. 18, No. 4. pp. 458-471.
@article{3a4dc17395e84b04a387e2e3e8b8e307,
title = "Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG 2) to arsenic trioxide-induced cell death",
abstract = "Intracellular redox homeostasis plays a critical role in determining tumor cells' sensitivity to drug-induced apoptosis. Here we investigated the role of thioredoxin-1 (TRX1), a key component of redox regulation, in arsenic trioxide (As 2 O 3)-induced apoptosis. Over-expression of wild-type TRX1 in HepG 2 cells led to the inhibition of As 2 O 3 -induced cytochrome c (cyto c) release, caspase activation and apoptosis, and down-regulation of TRX1 expression by RNAi sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. Interestingly, mutation of the active site of TRX1 from Cys 32/35 to Ser 32/35 converted this molecule from an apoptotic protector to an apoptotic promoter. In an effort to understand the mechanisms of this conversion, we used isolated mitochondria from mouse liver and found that recombinant wild-type TRX1 could protect mitochondria from the apoptotic changes. In contrast, the mutant form of TRX1 alone elicited mitochondria-related apoptotic changes, including the mitochondrial permeability transition pore (mPTP) opening, loss of mitochondrial membrane potential, and cyto c release from mitochondria. These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP. Alteration of TRX1 from its reduced form to oxidized form in vivo by 2,4- dinitrochlorobenzene (DNCB), a specific inhibitor of TRX reductase, also sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. These data suggest that TRX1 plays a central role in regulating apoptosis by blocking cyto c release, and inactivation of TRX1 by either mutation or oxidization of the active site cysteines may sensitize tumor cells to As 2 O 3 -induced apoptosis.",
keywords = "Apoptosis, Arsenic trioxide, Cytochrome c, Hioredoxin-1, Mitochondria",
author = "Changhai Tian and Ping Gao and Yanhua Zheng and Wen Yue and Xiaohui Wang and Haijing Jin and Quan Chen",
year = "2008",
month = "4",
day = "1",
doi = "10.1038/cr.2007.112",
language = "English (US)",
volume = "18",
pages = "458--471",
journal = "Cell Research",
issn = "1001-0602",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG 2) to arsenic trioxide-induced cell death

AU - Tian, Changhai

AU - Gao, Ping

AU - Zheng, Yanhua

AU - Yue, Wen

AU - Wang, Xiaohui

AU - Jin, Haijing

AU - Chen, Quan

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Intracellular redox homeostasis plays a critical role in determining tumor cells' sensitivity to drug-induced apoptosis. Here we investigated the role of thioredoxin-1 (TRX1), a key component of redox regulation, in arsenic trioxide (As 2 O 3)-induced apoptosis. Over-expression of wild-type TRX1 in HepG 2 cells led to the inhibition of As 2 O 3 -induced cytochrome c (cyto c) release, caspase activation and apoptosis, and down-regulation of TRX1 expression by RNAi sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. Interestingly, mutation of the active site of TRX1 from Cys 32/35 to Ser 32/35 converted this molecule from an apoptotic protector to an apoptotic promoter. In an effort to understand the mechanisms of this conversion, we used isolated mitochondria from mouse liver and found that recombinant wild-type TRX1 could protect mitochondria from the apoptotic changes. In contrast, the mutant form of TRX1 alone elicited mitochondria-related apoptotic changes, including the mitochondrial permeability transition pore (mPTP) opening, loss of mitochondrial membrane potential, and cyto c release from mitochondria. These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP. Alteration of TRX1 from its reduced form to oxidized form in vivo by 2,4- dinitrochlorobenzene (DNCB), a specific inhibitor of TRX reductase, also sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. These data suggest that TRX1 plays a central role in regulating apoptosis by blocking cyto c release, and inactivation of TRX1 by either mutation or oxidization of the active site cysteines may sensitize tumor cells to As 2 O 3 -induced apoptosis.

AB - Intracellular redox homeostasis plays a critical role in determining tumor cells' sensitivity to drug-induced apoptosis. Here we investigated the role of thioredoxin-1 (TRX1), a key component of redox regulation, in arsenic trioxide (As 2 O 3)-induced apoptosis. Over-expression of wild-type TRX1 in HepG 2 cells led to the inhibition of As 2 O 3 -induced cytochrome c (cyto c) release, caspase activation and apoptosis, and down-regulation of TRX1 expression by RNAi sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. Interestingly, mutation of the active site of TRX1 from Cys 32/35 to Ser 32/35 converted this molecule from an apoptotic protector to an apoptotic promoter. In an effort to understand the mechanisms of this conversion, we used isolated mitochondria from mouse liver and found that recombinant wild-type TRX1 could protect mitochondria from the apoptotic changes. In contrast, the mutant form of TRX1 alone elicited mitochondria-related apoptotic changes, including the mitochondrial permeability transition pore (mPTP) opening, loss of mitochondrial membrane potential, and cyto c release from mitochondria. These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP. Alteration of TRX1 from its reduced form to oxidized form in vivo by 2,4- dinitrochlorobenzene (DNCB), a specific inhibitor of TRX reductase, also sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. These data suggest that TRX1 plays a central role in regulating apoptosis by blocking cyto c release, and inactivation of TRX1 by either mutation or oxidization of the active site cysteines may sensitize tumor cells to As 2 O 3 -induced apoptosis.

KW - Apoptosis

KW - Arsenic trioxide

KW - Cytochrome c

KW - Hioredoxin-1

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=41849089734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849089734&partnerID=8YFLogxK

U2 - 10.1038/cr.2007.112

DO - 10.1038/cr.2007.112

M3 - Article

VL - 18

SP - 458

EP - 471

JO - Cell Research

JF - Cell Research

SN - 1001-0602

IS - 4

ER -